Express News | GlaxoSmithKline and curevac have redrafted their mRNA vaccine collaboration agreement

Breakings14:44

CureVac to Cut 30% of Workforce as GSK Buys Rights to Make Flu, Covid Shots

Seeking Alpha33minutes ago

US stock market abnormal <strong>Curevac</strong> rose nearly 20% before the market, expanded the mRNA vaccine cooperation agreement with <strong>GlaxoSmithKline</strong>, and planed to cut 30% of staff.

On July 3, Gelunhui, CureVac (CVAC.US), a German vaccine company, rose nearly 20% before pre-market trading, reporting $4. On the news front, GlaxoSmithKline and CureVac have redrafted their mRNA vaccine collaboration agreement in a new licensing agreement, giving GlaxoSmithKline the full rights to develop flu and COVID-19 candidate vaccines (including combination vaccines). CureVac will receive a prepayment of 400 million euros, as well as up to 1.05 billion euros in milestones and royalties. In addition, CureVac has begun a global strategy reorganization plan, which includes a 30% reduction in staff.

Gelonghui Finance35minutes ago

Curevac (CVAC.US) rose more than 15% before the market opened. Sell the copyright of flu and COVID-19 vaccines to GlaxoSmithKline (GSK.US).

Pharmaceutical giant GlaxoSmithKline (GSK.US) announced on Wednesday that it is restructuring its partnership with German biotech company CureVac (CVAC.US), and will take full control and takeover of several vaccines jointly developed by the two companies.

Zhitong Finance37minutes ago

After falling to an 11-year low and consolidating for several months, should I buy or sell pfizer (PFE.US) now?

In April of this year, Pfizer (PFE.US) stock price fell to its lowest point since January 2013. As of the closing price on July 1, the stock has risen by about 11% since then; After falling to an 11-year low, Pfizer has been consolidating for several months. So, should you buy or sell Pfizer stocks now? From a fundamental perspective, Pfizer is still trying to overcome the drag from the cooling of its COVID-19 products and actively promote the development of non-COVID-19 drug business. Recently, the company announced positive trial results of two potential anticancer drugs, but also closed a gene therapy project, and the company's stock price continues to trade sideways. In a study, patients who received Pfizer Elrex

Zhitong Finance15:22

GSK and CureVac Restructure Partnership, Focusing on MRNA Vaccine Development

GSK plc (NYSE:GSK) and CureVac N.V. (NASDAQ:CVAC) today announced they have restructured their existing collaboration into a new licensing agreement, allowing each company to prioritize investment and

Benzinga14:53